Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

Next Previous
X
Search
Trial Profile

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Antiemetics; Methotrexate; Methylprednisolone
  • Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ITCC-059

    • Most Recent Events

    • 27 May 2024 According to the Pfizer Media Release, based on results from two clinical trials (INO-Ped-ALL-1 and ITCC-059), company today announced that it has received approval for a partial change in drug manufacturing and marketing approval items for Besponsa in Japan for the treatment of pediatric relapsed or refractory CD22-positive acute lymphoblastic leukemia.
    • 27 May 2024 According to the Pfizer Media Release, the company submitted an application today, for approval of a partial change to the manufacturing and marketing approval items for inotuzumab ozogamicin (recombinant) preparation "Besponsa", is application is based on the results of a domestic Phase 1 study (INO-Ped-ALL-1 study: investigator-initiated clinical trial) and an overseas Phase 1/2 study (ITCC-059 study: investigator-initiated clinical trial).
    • 13 Dec 2022 Results from the ITCC-059 phase IA and phase II trial presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top